The combination of fludarabine, cyclophosphamide, and granulocyte-macrophage colony-stimulating factor in the treatment of patients with relapsed chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma

Clinical Lymphoma

Volumn 6, Issue 1, 2005, Pages 26-30

  Rao, Ruta ^a   Shammo, Jamile M ^a   Enschede, Sari H ^a   Porter, Carlene ^a   Adler, Solomon S ^a   Venugopal, Parameswaran ^a   Gregory, Stephanie A ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Alkylating agents; Cytopenia; Neutropenia; Nucleoside analogues

Indexed keywords

ALKYLATING AGENT; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; FLUDARABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PREDNISONE;

ADULT; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER PATIENT; CANCER RELAPSE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; EMBOLISM; EPISTAXIS; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INCIDENCE; INFECTION; MALE; MEDICAL ASSESSMENT; MYALGIA; NEUTROPENIA; NONHODGKIN LYMPHOMA; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; SYNCOPE; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT OUTCOME; URINARY FREQUENCY; URINARY URGENCY; VARICELLA ZOSTER VIRUS; VIRUS PNEUMONIA; WOUND INFECTION; ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; CYTOPENIA; DRUG RESPONSE; LEUKEMIA RELAPSE; PNEUMONIA;

EID: 22944437462     PISSN: 15269655     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2005.n.023     Document Type: Article

References (21)

1. Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. Blood 2000; 343:1750-1757.
2. Keating MJ, O'Brien S, Kantarjian H, et al. Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood 1993; 81:2878-2884.
3. O'Brien SM, Kantarjian K, Cortes J, et al. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol 2001; 19:1414-1420.
4. Peters BG, Adkins DR, Harrison BR, et al. Antifungal effects of yeast-derived rhu-GM-SCF in patients receiving high-dose chemotherapy given with or without autologous stem cell transplantation: a retrospective analysis. Bone Marrow Transplant 1996; 18:93-102.
5. Adefka D, Maor Y, Novick D, et al. Interleukin-6 inhibits the proliferation of B-chronic lymphocytic leukemia cells that is induced by tumor necrosis factor-alpha or -beta. Blood 1993; 81:2076-2084.
6. van Kooten C, Rensink I, Aarden L, et al. Effect of IL-4 and IL-6 on the proliferation and differentiation of B-chronic lymphocytic leukemia cells. Leukemia 1993; 7:618-624.
7. Munn DH, Garnick MB, Cheung NK, et al. Effects of parenteral recombinant human macrophage colony-stimulating factor on monocyte number, phenotype, and antitumor cytotoxicity in nonhuman primates. Blood 1990; 75:2042-2048.
8. Munn DH, Cheung NK. Phagocytosis of tumor cells by human monocytes cultured in recombinant macrophage colony-stimulating factor. J Exp Med 1990; 172:231-237.
9. Munn DH, Cheung NH. Antibody-dependent antitumor cytotoxicity by human monocytes cultured with recombinant macrophage colony-stimulating factor. Induction of efficient antibody-mediated antitumor cytotoxicity not detected by isotope release assays. J Exp Med 1989; 170:511-526.
10. Grabstein KH, Urdal DL, Tushkinski RJ, et al. Induction of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factor. Science 1986; 232:506-508.
11. Thomassen MJ, Ahmad M, Barna BP, et al. Induction of cytokine messenger RNA and secretion in alveolar macrophages and blood monocytes from patients with lung cancer receiving granulocyte-macrophage colony-stimulating factor therapy. Cancer Res 1991; 51:857-862.
12. Morrissey PJ, Bressler L, Charrier K, et al. Response of resident murine peritoneal macrophages to in vivo administration of granulocyte-macrophage colony-stimulating factor. J Immunol 1988; 140:1910-1915.
13. Charak BS, Agah R, Mazumder A. Granulocyte-macrophage colony-stimulating factor-induced antibody-dependent cellular cytotoyicity in bone marrow macrophages: application in bone marrow transplantation. Blood 1993; 81:3474-3479.
14. Sanda MG, Bolton E, Male JJ, et al. In vivo administration of recombinant macrophage colony-stimulating factor induces macrophage-mediated antibody-dependent cytotoxicity of minor cells. J Immunother 1992; 12:132-137.
15. Cheson BD, Bennet JM, Rai KR, et al. Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored working group. Am J Hematol 1988; 29:152-163.
16. Eichhorst BF, Busch R, Hopfinger G, et al. Fludarabine plus cyclophosphamide (FC) induces higher remission rates and longer progression free survival (PFS) than fludarabine (F) alone in first line therapy of advanced chronic lymphocytic leukemia (CLL): results of a phase III study (CLL4 protocol) of the German CLL Study Group (GCLLSG). Blood 2003; 102:72a (Abstract #243).
17. Lossos IS, Paltiel O, Polliack A. Salvage chemotherapy using a combination of fludarabine and cyclophosphamide for refractory or relapsing indolent and aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 1999; 33:155-160.
18. O'Brien S, Kantarjian H, Beran M, et al. Fludarabine and granulocyte colony-stimulating factor (G-CSF) in patients with chronic lymphocytic leukemia. Leukemia 1997; 11:1631-1635.
19. Kwak LW, Young HA, Pennington RW, et al. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response. Proc Natl Acad Sci 1996; 93:10972-10977.
20. Wierda W, O'Brien S, Albitar M, et al. Combined fludarabine, cyclophosphamide and rituximab achieves a high complete remission rate as initial treatment for chronic lymphocytic leukemia. Blood 2001; 98:771 (Abstract #3210).
21. Garcia Manero G, O'Brien S, Cortes J, et al. Update of results on the combination of fludarabine, cyclophosphamide and rituximab for previously treated patients with chronic lymphocytic leukemia (CLL). Blood 2001; 98:633a (Abstract #2650).